Edition:
United States

Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

1.20USD
15 Dec 2017
Change (% chg)

$-0.03 (-2.44%)
Prev Close
$1.23
Open
$1.21
Day's High
$1.24
Day's Low
$1.18
Volume
31,157
Avg. Vol
30,679
52-wk High
$5.69
52-wk Low
$1.16

Chart for

About

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management... (more)

Overall

Beta: 2.37
Market Cap(Mil.): $18.52
Shares Outstanding(Mil.): 15.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Man Group Plc Reports 8.54 Pct Passive Stake In Orexigen Therapeutics

* MAN GROUP PLC REPORTS 8.54 PERCENT PASSIVE STAKE IN OREXIGEN THERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING‍​ Source text : http://bit.ly/2AKRpMo Further company coverage:

Dec 01 2017

BRIEF-Orexigen Says Entered Into Exchange Agreements With Holders

* OREXIGEN - ENTERED INTO EXCHANGE AGREEMENTS WITH HOLDERS OF 2.75% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2020, 2.75% CONVERTIBLE SENIOR NOTES DUE 2020

Dec 01 2017

BRIEF-Orexigen Therapeutics Q3 loss per share $1.35

* Orexigen Therapeutics announces third quarter 2017 financial results

Nov 13 2017

BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt

* Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America

Nov 13 2017

BRIEF-Orexigen Therapeutics - pursuing potential actions including merger or sale of co

* Orexigen Therapeutics Inc says ‍expects total revenues for Q3 of 2017 to be between about $18.1 million and $19.1 million-SEC filing​

Oct 16 2017

BRIEF-Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030

* Orexigen announces favorable decision from U.S. District Court in patent litigation, confirming exclusivity for Contrave through 2030

Oct 13 2017

BRIEF-Orexigen Therapeutics sees 2017 net sales $85 mln to $100 mln - presentation slides‍​

* Orexigen Therapeutics Inc sees Orexigen net sales $85 million to $100 million for 2017 - presentation slides‍​ Source text: (http://bit.ly/2fpwCRS) Further company coverage:

Sep 26 2017

BRIEF-Orexigen Therapeutics to provide business update

* Orexigen Therapeutics to provide business update at the 2017 Cantor Fitzgerald Global Healthcare Conference Source text for Eikon: Further company coverage:

Sep 13 2017

BRIEF-Orexigen Therapeutics Q2 loss per share $2.00

* Orexigen Therapeutics announces second quarter 2017 financial results

Aug 08 2017

BRIEF-Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria

* Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria

Aug 07 2017

Earnings vs. Estimates